


Supplementary Table 1.

Primer name	Sequence	Description
CD98-F	5'-GAGGACAGGCTTTTGATTGC-3'	CD98 gene RT-PCR forward primer
CD98-R	5'-ATTCAGTACGCTCCCCAGTG-3'	CD98 gene RT-PCR reverse primer
TNF $\alpha$ -F	5'-AGGCTGCCCCGACTACGT-3'	Tumor necrosis factor gene RT-PCR forward primer
TNF $\alpha$ -R	5'-GAC TTTCTCCTGGTATGAGATAGCAAA-3'	Tumor necrosis factor gene RT-PCR reverse primer
IL6-F	5'-ACAAGTCGGAGGCTTAATTACACAT-3'	Interleukin 6 gene RT-PCR forward primer
IL6-R	5'-TTGCCATTGCACAACCTCTTTTC-3'	Interleukin 6 gene RT-PCR reverse primer
IL12-F	5'-GCCAGTACACCTGCCACAAA-3'	Interleukin 12 gene RT-PCR forward primer
IL12-R	5'-TGTGGAGCAGCAGATGTGAGT-3'	Interleukin 12 gene RT-PCR reverse primer
36B4-F	5'-TCCAGGCTTTGGGCATCA-3'	36B4 gene RT-PCR forward primer
36B4-R	5'-CTTTATCAGCTGCACATCACTCAGA-3'	36B4 gene RT-PCR reverse primer

Supplementary Figure 1.


Xiao B. et al.



ACCEPTED MANUSCRIPT





## Supplementary Figure 2.

Xiao B. et al.



## Supplementary Figure 3.


Xiao B. et al.

**A****B****C****D**

AC

## Supplementary Figure 4.


Xiao B. et al.



ACCEPTED


Supplementary Figure 5.

Xiao B. et al.




Supplementary Figure 6.

Xiao B. et al.



Supplementary Figure 7.

Xiao B. et al.




ACCEPTED MANUSCRIPT




## Supplementary Figure 8.

Xiao B. et al.



## Supplementary Figure 9.


Xiao B. et al.



ACCEPTED MANUSCRIPT


## Supplementary Figure 10.

Xiao B. et al.




## Supplementary Figure 11.

Xiao B. et al.




## Supplementary Figure 12.

Xiao B. et al.




Supplementary Figure 13.

Xiao B. et al.



## Supplementary Figure 14.

Xiao B. et al.



1 **Nanoparticles with Surface Antibody Against CD98 and Carrying CD98 Small Interfering**  
2 **RNA Reduce Colitis in Mice**

3 **Supplementary Materials and Methods**

4 **Preparation and Characterization of scCD98-PEG-UAC**

5 The synthetic strategy of scCD98-PEG-UAC is outlined in **Supplementary Figure 1**. Chitosan  
6 (Sigma) was obtained by further deacetylating and depolymerizing commercial chitosan using  
7 alkali treatment and sodium nitrite, respectively. Degree of deacetylation of chitosan was  
8 estimated as 95.6% by  $^1\text{H}$  NMR. Molecular weight of the resultant chitosan was measured as  
9 11.4 kDa by MOLDI-TOF. The UAC sample was synthesized described in previous report [1].  
10 UAC-PEG-MAL was prepared in phosphate-buffer solution (PBS, pH = 7.2) through specific  
11 reaction between UAC and the NHS groups of bifunctional PEG derivative (NHS-PEG-MAL,  
12 MW 2000, Jenkem, Beijing, China) at the mole ratio of 1:4 overnight while stirring. The  
13 resulting conjugate was purified by ultrafiltration with an Amicon<sup>®</sup> Ultra (regenerated cellulose  
14 membrane, MWCO = 10 kDa, Millipore). Meanwhile, CD98 antibody (Biolegend) was reduced  
15 to single-chain CD98 antibody (scCD98) using 2-mercapto ethylamine (Sigma). Then MAL-  
16 PEG-UAC was reacted with scCD98 at mole ratio of 1:2 in PBS (pH = 7.2) for 24 h at room  
17 temperature. The terminal MAL groups of MAL-PEG-UAC were specifically reacted with the  
18 thiol groups of scCD98, resulting in scCD98-PEG-UAC. Unreacted maleimide groups were  
19 quenched with 5 eq. cysteine. The final conjugates were lyophilized and characterized by FT-IR  
20 and  $^1\text{H}$  NMR. SDS-PAGE was used to demonstrate the full reaction of thiolated scCD98.  
21 Infrared spectra of chitosan and its derivatives were recorded with a Varian 600-UMA FT-IR  
22 microscope equipped with a liquid  $\text{N}_2$  cooled HgCdTe detector and coupled to a Varian 7000 FT-  
23 IR spectrometer. NMR spectrum was recorded on a Bruker Avance spectrometer (INOVA-600



## Supplementary Figure 15.

Xiao B. et al.

